New Medical Technology: A Mind Genomics Cartography of How to Present Ideas to Consumers and to Investors

Today’s world is awash in technology. The opportunities for making money through technology emerge when the benefits of the technology can be communicated either to users or to investors or both. In the world of startup accelerators, hungry investors, and the public which has learned to accept the blistering pace of innovation as part of today. It has become increasingly important to communicate one’s invention in a way which convinces the listener and excites the potential investor. It should not be surprising then that there are classes on creating the so-called ‘pitch deck,’ the document designed to excite investors. There is a lot less interest in finding out just what information might excite the prospective purchasers, simply because, in the scheme of things, starting up and raising money are more important than initial and then repeat sales. It is no wonder that many companies know what to say to investors about the financial aspects of the product but do not know what to say about the product itself. That is, these start-ups but also many later stage companies are at a loss to describe the mind of their investors and/or the mind of their customers. This means that, when challenged, virtually all startups struggle, having overlooked the relatively minor effort to really understand in a scientific, discipline manner, people’s reactions to what they are offering. With that in mind, the opportunity arose to use Mind Genomics for a new product idea, patented in the U.S. (Patent No. US 10,340,546 B1) on Jul 2, 2019 (Figure 1). Simply put, the device is a biocompatible, self-recharging micro battery, as small as a grain of rice, that can be safely and effectively implanted within the human body to power at least one implanted medical device, using the patient’s own body fluids. This micro-battery can communicate with the physician, giving advance warning of an imminent heart attack or the presence of a serious communicable disease. The idea is new, revolutionary, and is in the pre-seed phase. The question is what kinds of messages about this product will excite people. To reiterate, messages mean the messages about the product, in terms of what it Research Article